

Condensed Interim Consolidated Financial Statements

(Expressed in Canadian Dollars)

March 31, 2023

NOTICE TO READER

Under National Instrument 51-102, Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of the unaudited condensed interim consolidated financial statements, they must be accompanied by a notice indicating that the unaudited condensed interim consolidated financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed interim consolidated financial statements of the Company have been prepared by, and are the responsibility of the management of The Tinley Beverage Company Inc.

The Company's independent auditor has not performed a review of these unaudited condensed interim consolidated financial statements in accordance with the standards established by the Chartered Professional Accountants of Canada for a review of interim financial statements by an entity's auditor.

The Tinley Beverage Company Inc.

Table of Contents

March 31, 2023

	Page
Consolidated Financial Statements	
Condensed Interim Consolidated Statements of Financial Position	4
Condensed Interim Consolidated Statements of Loss and Comprehensive Loss	5
Condensed Interim Consolidated Statements of Changes in Shareholders' Equity	6
Condensed Interim Consolidated Statements of Cash Flows	7
Notes to Condensed Interim Consolidated Financial Statements	8-26

Condensed Interim Consolidated Statements of Financial Position As at March 31, 2023 and December 31, 2022

(Unaudited - Expressed in Canadian Dollars)

	As at March 31, 2023	As at December 31, 2022
	\$	\$
Assets		
Current Assets	4=0.200	102 (22
Cash	159,390	183,623
Accounts receivable (Note 4)	253,923	208,653
Inventories (Note 5)	432,663	418,190
Prepaid expenses (Note 7)	130,504	166,440
Total Current Assets	976,480	976,906
Non-Current Assets		
Property and equipment (Note 8)	5,360,738	5,659,104
Right-of-use assets (Note 10)	108,359	271,116
Security deposit	143,734	143,851
Note receivable (Note 6)	36,859	36,001
Total Non-Current Assets	5,649,690	6,110,072
Total Assets	6,626,170	7,086,978
Liabilities		
Current Liabilities		
Accounts payable and accrued liabilities (Note 9)	1,043,493	915,994
Deferred revenue	271,384	252,237
Current portion of lease liabilities (Note 10)	179,241	400,493
Convertible note (Note 11)	773,280	614,621
Convertible note – embedded derivative (Note 11)	2,063	82,144
Total Current Liabilities	2,269,461	2,265,489
Non-Current Liabilities		
Convertible grid note (Note 12)	1,581,604	992,473
Convertible grid note – embedded derivative (Note 12)	773,409	1,610,446
Total Non-Current Liabilities	2,355,013	2,602,919
Total Liabilities	4,624,474	4,868,408
Shareholders' Equity		
Share capital (Note 13)	42,192,513	42,192,513
Reserve for share-based payments (Note 14)	5,805,991	5,722,629
Reserve for warrants (Note 15)	7,384,824	7,384,824
Contributed surplus	7,436,623	7,436,623
Accumulated other comprehensive loss	(142,685)	(136,757)
Accumulated deficit	(60,675,570)	(60,381,262)
Total Shareholders' Equity	2,001,696	2,218,570
Total Liabilities and Shareholders' Equity	6,626,170	7,086,978

Nature of operations (Note 1) Going concern (Note 2(b)) Contingencies (Note 20) Subsequent events (Note 21)

Approved on behalf of the Board of Directors

<u>"Paul Burgis" (signed) - Director</u> <u>"Theodore Zittell" (signed)</u> - Director

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements

Condensed Interim Consolidated Statements of Loss and Comprehensive Loss For the Three Months ended March 31, 2023 and 2022

(Unaudited - Expressed in Canadian Dollars)

	2023	2022
	\$	\$
Sales	557,091	171,175
Cost of goods sold (Note 5)	(343,346)	(63,677)
Gross profit	213,745	107,498
Operating Expenses		
General and administration (Note 18)	762,232	927,014
Depreciation of property and equipment (Note 8)	287,227	252,061
Depreciation of right-of-use assets (Note 10)	162,453	152,076
Sales and marketing	130,777	197,205
Share-based payments (Notes 14)	83,362	100,612
Product development	33,297	174,625
Foreign currency translation loss (gain)	(136,496)	416
	1,322,852	1,804,009
Net loss before Other Income	(1,109,107)	(1,696,511)
Other Income		
Change in fair value of embedded derivatives (Note 11 & 12)	1,162,821	-
Gain on sale of vehicle	41,714	-
Interest income	889	-
Interest and accretion on convertible notes (Note 11 & 12)	(390,625)	
Net Loss	(294,308)	(1,696,511)
Other Comprehensive Income (Loss)		
Loss on translation of foreign operations	(5,928)	(81,033)
Comprehensive Loss	(300,236)	(1,777,544)
We's lated Amount New Lond Community Change On Artist Pro-	150.050.565	144.056.700
Weighted Average Number of Common Shares Outstanding	150,859,565	144,056,790
Net Loss per Share		
Basic and Diluted	(0.002)	(0.012)

Condensed Interim Consolidated Statements of Changes in Shareholders' Equity For the Three Months ended March 31, 2023 to 2022 (Unaudited - Expressed in Canadian Dollars)

	Share C	apital	Reser	ves				
	Number of		Share-based		Contributed	Accumulated	Accumulated other	
	shares	Amount	payments	Warrants	surplus	deficit	comprehensive loss	Total
	#	\$	\$	\$	\$	\$	\$	\$
Balance, December 31, 2021	144,112,042	41,520,254	6,052,920	8,701,200	4,993,337	(54,210,038)	(512,858)	6,544,815
Issuance of shares and warrants via private placements (Note 13)	5,530,666	581,127	-	262,307	-	-	-	843,434
Share issuance costs (Notes 13 and 15)	-	(36,638)	-	(15,620)	-	-	-	(52,258)
Share-based payments (Note 14)	-	-	100,612	-	-	-	-	100,612
Exchange loss on translation of foreign operations	-	-	-	-	-	-	(81,033)	(81,033)
Net loss for the period		-	-	=		(1,696,511)		(1,696,511)
Balance, March 31, 2022	149,642,708	42,064,743	6,153,532	8,947,887	4,993,337	(55,906,549)	(593,891)	5,659,059
Balance, December 31, 2022	150,859,565	42,192,513	5,722,629	7,384,824	7,436,623	(60,381,262)	(136,757)	2,218,570
Share-based payments (Note 14)	-	-	83,362	-	-	-	-	83,362
Exchange gain on translation of foreign operations	-	-	-	-	-	-	(5,928)	(5,928)
Net loss for the period	-	-	-	-	-	(294,308)	-	(294,308)
Balance, March 31, 2023	150,859,565	42,192,513	5,805,991	7,384,824	7,436,623	(60,675,570)	(142,685)	2,001,696

Condensed Interim Consolidated Statements of Cash Flows For the Three Months ended March 31, 2023 and 2022 (Unaudited - Expressed in Canadian Dollars)

	2023	2022
	\$	\$
Operating Activities		
Net loss for the period	(294,308)	(1,696,511)
Adjustments for non-cash items:		
Share-based payments (Note 14)	83,362	100,612
Depreciation of property and equipment (Note 8)	287,227	252,061
Depreciation of right-of-use assets (Note 10)	162,453	152,076
Change in fair value of embedded derivatives	(1,162,821)	-
Gain on sale of vehicle	(41,714)	-
Interest income	(889)	-
Interest on lease obligations (Note 10)	6,412	28,383
Interest and accretion	ŕ	
on convertible notes (Notes 11 and 12)	390,625	-
	(569,653)	(1,163,379)
Changes in non-cash working capital:		
Accounts receivable (Note 4)	(45,270)	(42,201)
Inventories (Note 5)	(14,473)	115,682
Prepaid expenses (Note 7)	35,936	80,118
Accounts payable and accrued liabilities (Note 9)	127,499	480,654
Deferred revenue	19,147	(79,330)
Cash Flows used in Operating Activities	(446,814)	(608,456)
Investing Activities		
Purchases of property and equipment (Note 8)	(23,583)	
Proceeds from sale of vehicle	* ' '	-
	70,718	(122.455)
Construction in progress	<u>-</u>	(133,455)
Cash Flows provided by (used in) Investing Activities	47,135	(133,455)
Financing Activities		
Proceeds from convertible grid note (Note 12)	741,115	_
Lease payments (Note 10)	(227,225)	(214,482)
Proceeds from private placements of shares (Note 13)	(221,223)	829,600
Share issue costs (Note 13)	_	(38,423)
Proceeds received from promissory note (Note 11)	- -	209,922
Cash Flows provided by Financing Activities	513,890	786,617
	2-2,22	, ,
Increase (Decrease) in cash for the period	114,211	44,706
Cash, beginning of period	183,623	113,840
Effects of foreign exchange on cash	(138,444)	3,715

Notes to the Condensed Interim Consolidated Financial Statements March 31, 2023

(Expressed in Canadian Dollars)

1. Nature of Operations

Tinley Beverage Company Inc. ("Tinley") was incorporated under the laws of the Province of Ontario, Canada by Articles of Incorporation dated October 26, 2007. Tinley, with its subsidiaries (see Note 2(c)) (together, the "Company"), manufactures a line of liquor-inspired, non-alcoholic, cannabis-infused beverages for use in California, United States ("US") and in Ontario, Canada. The Company also manufactures a line of liquor-inspired, non-alcoholic, non-cannabis-infused beverages, which are available in retail locations in the US and parts of Canada. The Company also manufactures cannabis-infused beverages for contract manufacturing clients. The Company's common shares are listed on the Canadian Securities Exchange under the trading symbol "TNY" and on the OTCQB under the trading symbol "TNYBF".

The address of the Company's registered office is 181 Bay Street, Suite 1800, Toronto, Ontario, M5J 2T9, Canada.

2. Basis of Presentation

(a) Statement of Compliance

The Company's condensed interim consolidated financial statements, including comparatives, have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). These condensed interim consolidated financial statements have been prepared in accordance with International Accounting Standards ("IAS") 34 'Interim Financial Reporting'. Accordingly, they do not include all of the information and disclosures required by IFRS for annual financial statements. For further information, see the Company's audited consolidated financial statements including the notes thereto for the year ended December 31, 2022.

These condensed interim consolidated financial statements were reviewed, approved and authorized for issuance by the Board of Directors of the Company (the "Board") on May 30, 2023.

(b) Going Concern

These condensed interim consolidated financial statements have been prepared with the assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. The application of the going concern basis is dependent upon the Company achieving profitable operations to generate sufficient cash flows to fund continuing operations, or, in the absence of adequate cash flows from operations, obtaining additional financing to support operations for the foreseeable future. It is not possible to predict whether future financing efforts will be successful or if the Company will attain profitable levels of operations.

For three months ended March 31, 2023, the Company had a net loss of \$294,308 (2022 – \$1,696,511), incurred negative cash flow from operations of \$446,814 (2022 – \$608,456), and as of that date, had a working capital deficiency of \$1,292,981 (December 31, 2022 – \$1,288,583) and an accumulated deficit of \$60,675,570 (December 31, 2022 – \$60,381,262). It is not possible to predict whether financing efforts will continue to be successful in the future or, if or when the Company will attain profitable levels of operations. These conditions, including the unpredictability of the cannabis-infused beverage business and the continued evolution of the novel coronavirus ("COVID-19") pandemic, represent material uncertainties which may cast doubt on the Company's ability to continue as a going concern.

These condensed interim consolidated financial statements do not give effect to adjustments that would be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and liquidate its liabilities and commitments in other than the normal course of business and at amounts different from those in the accompanying condensed interim consolidated financial statements. Such adjustments could be material.

(c) Basis of Consolidation

These condensed interim consolidated financial statements have been prepared in accordance with IFRS, on the historical cost basis except for certain financial instruments which are measured at fair value. In addition, these condensed interim consolidated financial statements have been prepared using the accrual basis of accounting, except for cash flow information.

These condensed interim consolidated financial statements include the accounts of Tinley and its wholly-owned subsidiaries: Hemplify Inc., Algonquin Springs Beverage Management LLC ("Algonquin"), Beckett's Tonics California Inc. (formerly Boardwalk Beverages, Inc.), Beckett's Tonics Canada Inc., Tinley's Canada Inc. and

Notes to the Condensed Interim Consolidated Financial Statements March 31, 2023

(Expressed in Canadian Dollars)

Lakewood Libations Inc. ("Lakewood"), as well as certain legacy dormant entities: Bolivar Gold Corp., QBC Holdings Corp., Kulta Corp., San Lucas Gold Corp. and Colombian Mining Corp.

Subsidiaries consist of entities over which the Company is exposed to, or has rights to, variable returns as well as the ability to affect those returns through the power to direct the relevant activities of the entity. Subsidiaries are fully consolidated from the date control is transferred to the Company and are-deconsolidated from the date control ceases.

The condensed interim consolidated financial statements include all the assets, liabilities, revenues, expenses and cash flows of Tinley and its subsidiaries after eliminating inter-entity balances and transactions.

(d) Significant Accounting Judgments and Estimates

The preparation of these condensed interim consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, revenue, and expenses. On an ongoing basis, management evaluates its judgments and estimates in relation to assets, liabilities, revenue, and expenses. Management uses historical experience and various other factors it believes to be reasonable under the given circumstances as the basis for its judgments and estimates. Actual outcomes may differ from these estimates under different assumptions and conditions. These estimates are reviewed periodically, and adjustments are made to income as appropriate in the period they become known. Items for which actual results may differ materially from these estimates are described as follows:

Going concern

At the end of each reporting period, management exercises judgment in assessing the Company's ability to continue as a going concern by reviewing its performance, resources and future obligations. The conclusion that the Company will be able to continue as a going concern is subject to critical judgments of management with respect to assumptions surrounding the short and long-term operating budgets, expected profitability, investment and financing activities and management's strategic planning. The assumptions used in management's going concern assessment are derived from actual operating results along with industry and market trends. Management believes there is sufficient capital to meet the Company's business obligations for at least the next 12 months, after taking into account expected cash flows, capital commitments, future financings and the Company's cash position at period-end.

Fair value of financial assets and financial liabilities

Fair value of financial assets and financial liabilities on the condensed interim consolidated statements of financial position that cannot be derived from active markets, are determined using a variety of techniques including the use of valuation models. The inputs to these models are derived from observable market data where possible, but where observable market data are not available, judgment is required to establish fair values. Judgments include, but are not limited to, consideration of model inputs such as volatility, estimated life and discount rates.

Notes to the Condensed Interim Consolidated Financial Statements March 31, 2023

(Expressed in Canadian Dollars)

Expected credit losses on financial assets

Determining an allowance for expected credit losses ("ECLs") for all debt financial assets not held at fair value through profit or loss requires management to make assumptions about the historical patterns for the probability of default, the timing of collection and the amount of incurred credit losses, which are adjusted based on management's judgment about whether economic conditions and credit terms are such that actual losses may be higher or lower than what the historical patterns suggest.

Determination of cash generating units

For the purpose of impairment testing, assets that cannot be tested individually are grouped at the lowest levels for which there are largely independent cash inflows. The Company determines which groups of assets (each a "Cash-Generating Unit" or a "CGU") can generate cash flows that are largely independent of other operations within the Company. Management exercises judgment in assessing where active markets exist including an analysis of the degree of autonomy each operation has in negotiating prices with customers. The Company has identified each product line as a separate CGU, based on the nature of the business and the assessment that the CGUs generate cash flows that are largely independent of the cash flows from other assets deployed in the Company.

Impairment

Long-lived assets, including property and equipment, are reviewed for indicators of impairment at each reporting period or whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds its recoverable amount. The recoverable amount of an asset or a CGU is the higher of its fair value less costs to sell, and its value-inuse. If the carrying amount of an asset exceeds its recoverable amount, an impairment charge is recognized immediately in profit or loss by the amount by which the carrying amount of the asset exceeds the recoverable amount.

Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the lesser of the revised estimate of recoverable amount, and the carrying amount that would have been recorded had no impairment loss been recognized previously.

Income taxes

Income taxes and tax exposures recognized in the consolidated financial statements reflect management's best estimate of the outcome based on facts known at the reporting date. When the Company anticipates a future income tax payment based on its estimates, it recognizes a liability. The difference between the expected amount and the final tax outcome has an impact on current and deferred taxes when the Company becomes aware of this difference.

In addition, when the Company incurs losses that cannot be associated with current or past profits, it assesses the probability of taxable profits being available in the future based on its budgeted forecasts. These forecasts are adjusted to take account of certain non-taxable income and expenses and specific rules on the use of unused credits and tax losses. When the forecasts indicate the sufficient future taxable income will be available to deduct the temporary differences, a deferred tax asset is recognized for all deductible temporary differences.

Share-based payment transactions and warrants

The Company measures the cost of equity-settled transactions with officers and directors by reference to the fair value of the equity instruments at the date at which they are granted. Estimating fair value for share-based payment transactions requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining and making assumptions about the most appropriate inputs to the valuation model including the expected life, volatility, dividend yield of the share option and forfeiture rate. Similar calculations are made in order to value warrants. Such judgments and assumptions are inherently uncertain. Changes in these assumptions will affect the fair value estimates.

3. Summary of Significant Accounting Policies

The accounting policies applied by the Company in these condensed interim consolidated financial statements are the same as those noted in the Company's consolidated financial statements as at and for the year ended December 31, 2022.

Notes to the Condensed Interim Consolidated Financial Statements March 31, 2023

(Expressed in Canadian Dollars)

4. Accounts Receivable

Accounts receivable consisted of the following:

	March 31,	December 31,
	2023	2022
	\$	\$
Trade receivables	219,514	166,330
Sales taxes recoverable	34,409	42,323
	253,923	208,653

5. Inventories

Inventories consisted of the following:

	March 31,	December 31,
	2023	2022
	\$	\$
Raw materials	317,417	292,464
Finished goods	115,246	120,397
Work in process	-	5,329
	432,663	418,190

For the three months ended March 31, 2023, inventories recognized as an expense in cost of goods sold amounted to \$343,346 (2022 - \$63,677).

6. Note Receivable

On August 12, 2022, ILLA Canna LLC, a related party controlled by a director of the Company, issued the Company a secured promissory note in the amount of \$37,071 (USD \$29,000) as part of the Company's sale of a vehicle. This amount represents 50% of the sale price of the vehicle; the other 50% was paid in cash. The promissory note is secured against the purchased vehicle. The maturity date of the promissory note is August 12, 2024. Interest accrues on the principal balance of the note at the rate of 10% per annum.

The following table reflects the continuity of the note receivable for the period ended March 31, 2023:

	\$
Balance, beginning of period	36,001
Accrued interest	889
Payments	-
Effect of foreign exchange	(31)
Balance, March 31, 2023	36,859

Notes to the Condensed Interim Consolidated Financial Statements March 31, 2023

(Expressed in Canadian Dollars)

7. Prepaid Expenses

Prepaid expenses consisted of the following:

	March 31,	December 31,
	2023	2022
	\$	\$
Advances paid to suppliers	28,951	70,099
Prepaid insurance	101,553	96,341
	130,504	166,440

8. Property and Equipment

		Leasehold		
	Plant Equipment	Improvements	Vehicles	Total
	\$	\$	\$	\$
Cost at:				
December 31, 2022	7,270,799	1,959,092	92,708	9,322,599
Additions	23,583	-	-	23,583
Dispositions	-	-	(92,585)	(92,585)
Effects of foreign exchange	(5,892)	(1,591)	(123)	(7,606)
March 31, 2023	7,288,490	1,957,501	-	9,245,991
Accumulated depreciation at:				
December 31, 2022	2,238,891	1,361,910	62,694	3,663,495
Dispositions	-	-	(62,612)	(62,612)
Depreciation	181,979	105,248	-	287,227
Effect of foreign exchange	(1,723)	(1,052)	(82)	(2,857)
March 31, 2023	2,419,147	1,466,106	-	3,885,253
Net Book Value:				
December 31, 2022	5,031,908	597,182	30,014	5,659,104
March 31, 2023	4,869,343	491,395	-	5,360,738

9. Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities consisted of the following:

	March 31,	December 31,
	2023	2022
	\$	\$
Trade payables	824,215	659,055
Accrued liabilities	219,278	256,939
	1,043,493	915,994

Accounts payable and accrued liabilities are principally comprised of amounts outstanding for trade purchases and other payables. The usual credit period taken for trade purchases is between 30 to 90 days.

Notes to the Condensed Interim Consolidated Financial Statements March 31, 2023

(Expressed in Canadian Dollars)

The following is a maturity analysis of the trade and other payables:

	March 31,	December 31,
	2023	2022
	\$	\$
Less than 1 month	483,667	414,390
1 to 3 months	163,753	123,909
Over 3 months	396,073	377,695
	1,043,493	915,994

10. Right-of-Use Assets and Lease Liability

On March 1, 2018, the Company entered into two lease agreements for the Long Beach facility, granting the Company a RUA for beverage production and bottling facilities. The leases commenced on March 1, 2018, with a term of five years and three months, ending May 31, 2023, with an option to renew for two additional 36-month periods.

On March 21, 2023, the Company decided not to renew its lease at its premises in Long Beach, California and to relocate its plant assets to Canoga Park. Management is still evaluating the costs involved and resulting impacts, potentially involving reclassification and remeasurement of certain leasehold assets.

The following is a summary of the RUA as at March 31, 2023:

Cost at:	
December 31, 2022	3,416,047
Additions	-
Effect of foreign exchange	(2,774)
March 31, 2023	3,413,273
Accumulated depreciation at:	
December 31, 2022	3,144,931
Depreciation	162,452
Effect of foreign exchange	(2,469)
March 31, 2023	3,304,914
Net book value:	
December 31, 2022	271,116
March 31, 2023	108,359

The following table reflects the changes in the lease payable on the Long Beach facility for the three months ended March 31, 2023:

Lease liability, beginning of period	400,493
Lease payments	(227,225)
Interest on lease obligations	6,412
Effect of foreign exchange	(439)
Total lease liability, end of period	179,241
Current	179,241
Non-current	-
	179,241

Notes to the Condensed Interim Consolidated Financial Statements March 31, 2023

(Expressed in Canadian Dollars)

Lease commitment consisted of the following:

	Total	Within 1 year	1 to 3 years	3 to 5 years
	\$	\$	\$	\$
Lease payable	179,241	179,241	-	-
Total	179,241	179,241	_	_

11. Convertible Note

On June 10, 2022, the Company issued a secured convertible note (the "Gillis Note") to the President of Tinley's USA branded products for \$782,272 (USD \$612,250) (the "Advance"). The principal amount of the Gillis Note is to be repaid, in cash, by the Company on the date which is one year following issuance of the Note (the "Maturity Date"), and bears interest at 12% per annum. The Gillis Note is convertible at the option of the holder into units (each being a "Unit") at the conversion price of \$0.105 per share (the "Conversion Price"). Each Unit would consist of one common share of the Company and one-half of one Warrant, with each whole Warrant exercisable for a period of two years from the date of issuance of such Warrant at an exercise price equal to the Conversion Price.

The Gillis Note is secured against the assets of the Company and the Company's US subsidiary, Algonquin, which security is second in priority behind the security of Blaze Life Holdings, LLC (defined hereafter in Note 12).

In the event of a Liquidity Event (defined as any one of the following events: (i) the approval by shareholders of the Corporation representing in the aggregate more than 50% of all issued and outstanding Common Shares of any offer, whether by way of a take-over bid, or otherwise, for all or any of the Common Shares; (ii) the acquisition hereafter, by whatever means (including, without limitation, by way of an arrangement, merger or amalgamation), by any person (or two or more persons acting jointly or in concert), directly or indirectly, of the beneficial ownership of Common Shares or rights to acquire Common Shares that, together with such person's then owned Common Shares and rights to acquire Common Shares, if any, represent in the aggregate more than 50% of all issued and outstanding Common Shares; or (iii) the sale by the Corporation of all or substantially all of its assets (other than to an affiliate of the Corporation in circumstances where the affairs of the Corporation are, directly or indirectly, and where holders of Common Shares remain substantially the same following the sale as existed prior to the sale)), all of the remaining indebtedness would automatically convert into Units at a 25% discount to the deemed price per common share paid in connection with the Liquidity Event, provided that such discounted deemed price shall be no less than \$0.05 per Unit.

The Gillis Note is a derivative financial instrument as the Gillis Note is denominated in US dollars, while convertible in Canadian dollars. As the conversion price in a different currency requires a variable number of shares to settle the Gillis Note, the Gillis Note is treated as having an embedded derivative that is treated as a financial liability under IFRS. On initial recognition, the derivative is recognized at fair value. The fair value of the derivative upon initial recognition was calculated to be \$384,743 using the Black Scholes valuation model. The difference between the principal amount of the Gillis Note and the derivative component of the note, has been allocated to the convertible note.

The fair value at issuance of the embedded derivative was determined using the Black Scholes valuation model using the following assumptions: stock price of \$0.11; expected life of 1.00 year; \$nil dividends; 119% volatility; risk-free interest of 3.35%; and the exercise price of \$0.105.

The fair value at December 31, 2022 of the embedded derivative was determined using the Black Scholes valuation model using the following assumptions: stock price of \$0.07; expected life of 0.44 years; \$nil dividends; 105% volatility; risk-free interest of 3.30%; and the exercise price of \$0.105.

The fair value at March 31, 2023 of the embedded derivative was determined using the Black Scholes valuation model using the following assumptions: stock price of \$0.035; expected life of 0.20 years; \$nil dividends; 123% volatility; risk-free interest of 2.90%; and the exercise price of \$0.105.

The embedded derivative is fair valued at each reporting date. The fair value as at March 31, 2023 is \$2,063 and the change in fair value resulted in a gain of \$80,081.

Notes to the Condensed Interim Consolidated Financial Statements March 31, 2023

(Expressed in Canadian Dollars)

The following table reflects the continuity of the convertible note and embedded derivative as at March 31, 2023:

	Convertible Note	Embedded Derivative
	\$	\$
Balance, beginning of period	614,621	82,144
Additions	-	-
Allocation to embedded derivative	-	-
Issuance cost	-	-
Accrued interest	24,504	-
Accretion	159,076	-
Change in fair value	-	(80,081)
Effect of foreign exchange	(24,921)	-
Balance, March 31, 2023	773,280	2,063

12. Convertible Grid Note

On June 10, 2022, the Company closed a financing of up to USD \$3.5 million through the issuance of a secured convertible grid note (the "BLH Note") to Blaze Life Holdings, LLC ("BLH"). The BLH Note bears interest at the rate of 12% per annum, and has a term of five years from the date of issuance. All indebtedness under the BLH Note, including all principal amounts advanced from time to time and accrued and unpaid interest, is convertible into Units at the option of BLH at a Conversion Price of \$0.105 per Unit. Each Unit would consist of one common share of the Company and one-half of one Warrant, with each whole Warrant exercisable for a period of two years from the date of issuance of such Warrant at an exercise price equal to the Conversion Price.

As a result of this transaction BLH became a related party.

As at March 31, 2023, the amount advanced under the BLH Note is \$4,194,170 (USD \$3.2 million) due on June 10, 2027. The assets of the Company and the Company's US subsidiary, Algonquin, are pledged against the BLH Note.

The BLH Note provides for the automatic conversion of: (i) 33.33% of the indebtedness under the BLH Note if the closing price of the common shares on the CSE exceeds \$0.50 for five consecutive trading days; (ii) an additional 33.33% of the indebtedness under the BLH Note if the closing price of the common shares on the CSE exceeds \$0.75 for five consecutive trading days; and (iii) the remaining 33.33% indebtedness under the BLH Note if the closing price of the common shares on the CSE exceeds \$1.00 for five consecutive trading days.

In connection with the issuance of the BLH Note, the Company issued 1,216,857 common shares as an advisory fee valued at \$127,770 (USD \$100,000) to a director of the Company. The advisory fees were included in share issue costs.

The BLH Note is a derivative financial instrument as the BLH Note is denominated in US dollars, while convertible in Canadian dollars. As the conversion price in a different currency requires a variable number of shares to settle the BLH Note, the BLH Note is treated as having an embedded derivative that is treated as a financial liability under IFRS. On initial recognition, the derivative is recognized at fair value. The fair value of the derivative upon initial recognition was calculated to be \$2,398,654 using the Black Scholes valuation model. The difference between the principal amount of the BLH Note and the derivative component of the note, has been allocated to the convertible note.

Notes to the Condensed Interim Consolidated Financial Statements March 31, 2023

(Expressed in Canadian Dollars)

The fair value of the embedded derivative as part of the June 10, 2022, initial instalment payment of \$1,277,700 (\$1,000,000 USD) was determined using the Black Scholes valuation model using the following assumptions: stock price of \$0.11; expected life of 5.00 years; \$nil dividends; 102% volatility; risk-free interest of 3.35%; and the exercise price of \$0.105.

The fair value of the embedded derivative as part of the July 4, 2022, instalment payment of \$643,350 (\$500,000 USD) was determined using the Black Scholes valuation model using the following assumptions: stock price of \$0.105; expected life of 4.94 years; \$nil dividends; 102% volatility; risk-free interest of 3.17%; and the exercise price of \$0.105.

The fair value of the embedded derivative as part of the August 4, 2022, instalment payment of \$642,700 (\$500,000 USD) was determined using the Black Scholes valuation model using the following assumptions: stock price of \$0.10; expected life of 4.85 years; \$nil dividends; 103% volatility; risk-free interest of 2.66%; and the exercise price of \$0.105.

The fair value of the embedded derivative as part of the October 24, 2022, instalment payment of \$686,100 (\$500,000 USD) was determined using the Black Scholes valuation model using the following assumptions: stock price of \$0.07; expected life of 4.63 years; \$nil dividends; 104% volatility; risk-free interest of 3.57%; and the exercise price of \$0.105.

The fair value of the embedded derivative as part of the December 13, 2022, instalment payment of \$203,205 (\$150,000 USD) was determined using the Black Scholes valuation model using the following assumptions: stock price of \$0.07; expected life of 4.49 years; \$nil dividends; 103% volatility; risk-free interest of 2.85%; and the exercise price of \$0.105.

The fair value of the embedded derivative as part of the February 1, 2023, instalment payment of \$466,235 (\$350,000 USD) was determined using the Black Scholes valuation model using the following assumptions: stock price of \$0.06; expected life of 4.36 years; \$nil dividends; 99% volatility; risk-free interest of 2.85%; and the exercise price of \$0.105.

The fair value of the embedded derivative as part of the March 16, 2023, instalment payment of \$274,880 (\$200,000 USD) was determined using the Black Scholes valuation model using the following assumptions: stock price of \$0.05; expected life of 4.24 years; \$nil dividends; 99% volatility; risk-free interest of 2.90%; and the exercise price of \$0.105.

The fair value at December 31, 2022 of the embedded derivative was determined using the Black Scholes valuation model using the following assumptions: stock price of \$0.07; expected life of 4.44 years; \$nil dividends; 101% volatility; risk-free interest of 3.30%; and the exercise price of \$0.105.

The fair value at March 31, 2023 of the embedded derivative was determined using the Black Scholes valuation model using the following assumptions: stock price of \$0.035; expected life of 4.20 years; \$nil dividends; 101% volatility; risk-free interest of 2.90%; and the exercise price of \$0.105.

The embedded derivative is fair valued at each reporting date. The fair value as at March 31, 2023 is \$773,409 and the change in fair value resulted in a gain of \$1,082,740.

Notes to the Condensed Interim Consolidated Financial Statements March 31, 2023

(Expressed in Canadian Dollars)

The following table reflects the continuity of the convertible note and embedded derivative as at March 31, 2023:

	Convertible	Embedded Derivative
	Note S	S S
	Ψ	Ψ
Balance, beginning of period	992,473	1,610,446
Additions	741,115	-
Allocation to embedded derivative	(245,703)	245,703
Issuance cost	-	-
Accrued interest	116,420	-
Accretion	90,625	-
Change in fair value	-	(1,082,740)
Effect of foreign exchange	(113,326)	-
Balance, March 31, 2023	1,581,604	773,409

Notes to the Condensed Interim Consolidated Financial Statements March 31, 2023

(Expressed in Canadian Dollars)

13. Share Capital

Authorized share capital

The Company is authorized to issue an unlimited number of common shares without par value.

Issued

Holders of the Company's common shares are entitled to receive dividends which may be declared from time to time and are entitled to one vote per share at shareholder meetings of the Company.

The following details the amounts recorded as share capital for the period:

	Number of shares	Proceeds	Share issuance costs	Allocated to reserve for warrants	Resulting share capital amount
	#	\$	\$	\$	\$
Balance, January 1, 2022	144,112,042	-	-	-	41,520,254
Issuance on private placement January 19, 2022 (a)	2,080,666	312,100	(3,912)	(93,917)	214,271
Issuance on private placement February 25, 2022 (b)	3,450,000	517,500	(32,726)	(154,556)	330,218
Balance, March 31, 2022	149,642,708	829,600	(36,638)	(248,473)	42,064,743
Balance, January 1, 2023	150,859,565	-	-	-	42,192,513
Balance, March 31, 2023	150,859,565	-	-	-	42,192,513

Included in the number of shares outstanding above, at no cost, are 3,000,000 common shares in escrow ("Escrow Shares") for the former Chief Executive Officer ("CEO") of the Company, who resigned on September 20, 2021. In accordance with a consulting agreement (the "Agreement") entered between the Company and the former CEO, dated October 29, 2015, the 3,000,000 Escrow Shares were originally to be issued at a price of \$0.05 per share, subject to performance based on the Company meeting a sales target within five years of the Agreement. The Company elected to extend the deadline for achieving these sales targets by two years. During the term of the Agreement, the Company is to release 1,500,000 Escrow Shares if sales exceed \$1 million over any four consecutive quarters. An additional 1,500,000 consideration shares are to be released if sales exceed \$3 million over any four consecutive quarters. The Escrow Shares were due to be returned and cancelled on October 29, 2022, however they still remain outstanding.

Share capital transactions for the three months ended March 31, 2022

- (a) On January 19, 2022, the Company closed a non-brokered private placement (the "January 2022 Offering") through the issuance of 2,080,666 Units at a price of \$0.15 per Unit, for gross proceeds of \$312,100. Each Unit is comprised of one common share of the Company and one Warrant. Each Warrant is exercisable into one common share at a price of \$0.20 until January 19, 2024.
- (b) On February 25, 2022, the Company closed a non-brokered private placement (the "February 2022 Offering") through the issuance of 3,450,000 Units at a price of \$0.15 per unit, for gross proceeds of \$517,500. Each Unit is comprised of one common share of the Company and one Warrant. Each Warrant is exercisable into one common share at a price of \$0.20 until February 25, 2024. In connection with the February 2022 Offering, the Company paid cash commissions of \$16,200 to the Agents. In addition, 108,000 Broker Warrants Type II were issued as compensation to the Agents (see Note 15 for details).

Share capital transactions for the three months ended March 31, 2023

There were no share capital transactions for the three months ended March 31, 2023.

14. Reserve for Share-Based Payments

The Company maintains a stock option plan to provide additional incentive to its officers, directors, employees, and consultants in their effort to conduct business on behalf of the Company. Options granted vest over a vesting period between two to five years. All options expire on the fifth anniversary from the date of grant unless otherwise specified.

Notes to the Condensed Interim Consolidated Financial Statements March 31, 2023

(Expressed in Canadian Dollars)

The following summarizes the options activities for the three months ended March 31, 2023 and 2022:

	202	3	2022	2
	Weighted	Number of	Weighted	Number of
	average	options	average	options
	exercise price	outstanding	exercise price	outstanding
	\$	#	\$	#
Outstanding, beginning of period	0.34	16,190,000	0.48	12,965,000
Granted	0.10	1,800,000	-	
Outstanding, end of period	0.32	17,990,000	0.48	12,965,000
Exercisable, end of period	0.32	17,902,500	0.49	10,902,916

Options grants for the three months ended March 31, 2022

No options were granted during the three months ended March 31, 2022.

Options grants for the three months ended March 31, 2023

On January 30, 2023, the Company granted 1,800,000 stock options to two directors and a management company controlled by a director at an exercise price of \$0.10 per share. The options expire on January 30, 2028. The options vested immediately.

Black-Scholes valuation assumptions

The grant date fair value of options was estimated using Black-Scholes with the following assumptions. Expected volatility was determined based on the historical volatility of the Company and comparable companies.

Options granted in 2023

	January 30,
Grant date	2023
Number of options	1,800,000
Exercise price per share	\$0.10
Share price	\$0.07
Expected life of options	5 years
Expected volatility	99.28%
Risk-free interest rate	3.04%
Forfeiture rate	10%

Notes to the Condensed Interim Consolidated Financial Statements March 31, 2023

(Expressed in Canadian Dollars)

The following table summarizes information of options outstanding as at March 31, 2023:

	Number of	Number of		Estimated	Weighted
	options	options	Exercise	grant date	average
Date of expiry	outstanding	exercisable	price	fair value	remaining life
	#	#	\$	\$	Years
April 20, 2023	100,000	100,000	0.87	68,282	0.05
August 13, 2023	300,000	300,000	0.79	126,429	0.37
November 30, 2023	2,050,000	2,050,000	0.58	877,362	0.67
November 30, 2023	900,000	900,000	0.58	385,183	0.67
December 11, 2023	100,000	100,000	0.58	41,139	0.70
December 14, 2023	250,000	250,000	0.58	107,028	0.71
September 4, 2024	275,000	275,000	0.56	222,965	1.43
November 14, 2024	200,000	200,000	0.37	67,384	1.63
December 23, 2024	2,050,000	2,050,000	0.41	632,487	1.73
December 23, 2024	290,000	290,000	0.41	89,474	1.73
October 25, 2025	200,000	200,000	0.37	57,083	2.57
January 27, 2026	2,400,000	2,400,000	0.41	711,848	2.83
February 24, 2026	400,000	400,000	0.47	127,417	2.91
March 9, 2026	100,000	100,000	0.50	31,864	2.94
March 9, 2026	100,000	100,000	0.70	30,356	2.94
March 9, 2026	100,000	100,000	1.00	28,609	2.94
August 17, 2026	300,000	225,000	0.23	47,031	3.38
September 29, 2026	25,000	12,500	0.17	2,869	3.50
September 15, 2027	6,050,000	6,050,000	0.10	314,392	4.46
January 30, 2028	1,800,000	1,800,000	0.10	79,920	4.84
	17,990,000	17,902,502	0.32	4,049,122	2.96

During the period ended March 31, 2023, the Company recognized share-based payments related to the vesting of stock options of \$83,362 (2022 - \$100,612).

Notes to the Condensed Interim Consolidated Financial Statements March 31, 2023

(Expressed in Canadian Dollars)

15. Reserve for Warrants

The following summarizes the warrant activities for the three months ended March 31, 2023 and 2022:

		2023		2022
	Number of		Number of	
	warrants		warrants	
	outstanding	Fair value	outstanding	Fair value
	#	\$	#	\$
Share purchase warrants				
Balance, beginning of period	28,234,580	6,993,469	32,921,414	8,012,238
Issued January 19, 2022	-	_	2,080,666	92,233
Issued February 25, 2022	-	-	3,450,000	140,620
Balance, end of period	28,234,580	6,993,469	38,452,080	8,245,091
Broker Warrants Type I ^(a)				
Balance, beginning of period	29,750	6,614	29,750	6,614
Balance, end of period	29,750	6,614	29,750	6,614
Broker Warrants Type II (b)				
Balance, beginning of period	1,340,010	384,741	1,936,777	682,348
Issued February 25, 2022	1,540,010	-	108,000	13,834
<u> </u>	<u> </u>		100,000	
Balance, end of period	1,340,010	384,741	2,044,777	696,182
Total	29,604,340	7,384,824	40,526,607	8,947,887

- (a) Broker Unit Purchase Warrants Type I are exercisable for one common share and one-half of one warrant exercisable into one common share.
- (b) Broker Unit Purchase Warrants Type II are exercisable for one common share and one warrant exercisable into one common share.

Warrant activities for the three months ended March 31, 2022

On January 19, 2022, the Company issued 2,080,666 Warrants, at an exercise price of \$0.20 per share, in connection with the January 2022 Offering as disclosed in Note 13(a).

On February 25, 2022, the Company issued 3,450,000 Warrants, at an exercise price of \$0.20 per share, in connection with the February 2022 Offering as disclosed in Note 13(b). In addition, 108,000 Broker Warrant Type II were issued as compensation to the Agents, to acquire one Unit at an exercise price of \$0.15 per Unit until February 25, 2024. Each Unit is comprised of one common share and one Warrant, exercisable into one common share at \$0.20 per share for a period of 24 months.

Black-Scholes valuation assumptions

The fair value of warrants issued was estimated using Black-Scholes with the following assumptions. Expected volatility was determined based on the historical volatility of the Company and comparable companies.

Notes to the Condensed Interim Consolidated Financial Statements March 31, 2023

(Expressed in Canadian Dollars)

Share purchase warrants issued in 2022

	February 25,	January 19,
Issuance date	2022	2022
Number of warrants	3,450,000	2,080,666
Exercise price	\$0.20	\$0.20
Share price	\$0.14	\$0.145
Expected life of warrants	2 years	2 years
Expected volatility	96.86%	96.31%
Risk-free interest rate	1.53%	1.27%

Broker Warrants Type II issued in 2022

	February 25,
Issuance date	2022
Number of warrants	108,000
Exercise price	\$0.15
Unit price	\$0.140
Expected life of warrants	2 years
Expected volatility	96.86%
Risk-free interest rate	0.72%

The following table summarizes information of warrants outstanding as at March 31, 2023:

	Number of warrants outstanding	Exercise price	Weighted average remaining life
	#	\$	\$
Share purchase warrants			
June 10, 2023	3,660,984	0.42	0.19
October 14, 2023	12,437,805	0.20	0.54
November 23, 2023	2,222,300	0.60	0.65
December 8, 2023	2,257,825	0.60	0.69
January 19, 2024	2,080,666	0.20	0.81
February 25, 2024	3,450,000	0.20	0.91
March 30, 2024	2,125,000	0.50	1.00
Balance, end of period	28,234,580	0.31	0.61

Notes to the Condensed Interim Consolidated Financial Statements March 31, 2023

(Expressed in Canadian Dollars)

	Number of warrants outstanding	Exercise price	Weighted average remaining life
	#	\$	\$
Broker Warrants Type I			
June 10, 2023	29,750	0.33	0.19
Balance, end of period	29,750	0.33	0.19
<u>Broker Warrants Type II</u>			
October 14, 2023	764,169	0.15	0.54
November 23, 2023	155,561	0.45	0.65
December 8, 2023	158,048	0.45	0.69
February 25, 2024	108,000	0.15	0.91
March 30, 2024	154,232	0.40	1.00
Balance, end of period	1,340,010	0.25	0.65

16. Related Party Transactions

Key management compensation

Key management personnel are persons responsible for planning, directing and controlling activities of an entity, and include executives and non-executive directors, officers and any employees. Compensation provided to key management personnel for the three months ended March 31, 2023 and 2022 were as follows:

	2023	2022
	\$	\$
Short-term employee benefits,		
including salaries and consulting fees	162,385	182,958
Share-based compensation	81,287	22,385
	243,672	205,343

- (i) During the three months ended March 31, 2023, the Company incurred consulting fees with the Chief Executive Officer ("CEO") and director of \$54,000 (2022 \$39,000) for services rendered. As at March 31, 2023, \$16,000 (December 31, 2022 \$27,425) was outstanding and included in accounts payable and accrued liabilities.
- (ii) During the three months ended March 31, 2023, the Company incurred consulting fees with the Chief Financial Officer ("CFO") of \$45,000 (2022 \$30,000) for services rendered. As at March 31, 2023, no balance (December 31, 2022 \$16,950) was outstanding.
- (iii) During the three months ended March 31, 2023, the Company incurred wage expenses with the former President of Tinley's USA branded products of \$41,635 (2022 \$75,972) for services rendered. As at March 31, 2023, no balance (December 31, 2022 \$nil) was outstanding.
- (iv) During the three months ended March 31, 2023, the Company incurred director fees with directors who are not part of key management of \$21,750 (2022 \$nil) for services rendered. As at March 31, 2023, \$16,250 (December 31, 2022 \$12,000) was outstanding and included in accounts payable and accrued liabilities.
- (v) During the three months ended March 31, 2022, the Company incurred consulting fees with a former director of \$37,989 for services rendered. As at March 31, 2022, no balance was outstanding.

Other related party transactions

(vi) During the three months ended March 31, 2023, directors who are not part of key management and a management company controlled by a director received stock-based compensation of \$79,920 (2022 – \$2,760).

Notes to the Condensed Interim Consolidated Financial Statements March 31, 2023

(Expressed in Canadian Dollars)

17. Capital Risk Management

When managing capital, the Company's objective is to ensure it continues as a going concern as well as to maintain optimal returns to shareholders and benefits for other stakeholders. Management adjusts the capital structure as necessary in order to support the beverage production.

The Board of the Company does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company's management team to sustain the future development of the business.

As at March 31, 2023, the Company considers its capital to be share capital, reserve for share-based payments, reserve for warrants, and contributed surplus, and reduced by accumulated deficit and accumulated other comprehensive loss, totaling \$2,001,696 (December 31, 2022 – \$2,218,570).

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable.

The Company is not subject to externally imposed capital requirements, and there were no changes in the Company's approach to capital management for the three months ended March 31, 2023.

Notes to the Condensed Interim Consolidated Financial Statements March 31, 2023

(Expressed in Canadian Dollars)

18. General and Administrative Expenses

The Company's general and administration expenses incurred for the three months ended March 31, 2023 and 2022 are as follows:

	2023	2022
	\$	\$
Payroll and salaries	340,050	389,047
Corporate costs and administration	232,830	258,883
Professional fees	78,984	190,202
Consulting and management fees	59,751	53,348
Occupancy costs	42,117	5,276
Interest on lease obligations	6,412	28,383
Travel and promotion	2,088	1,875
	762,232	927,014

19. Financial Instruments and Risk Management

Fair value

The carrying amount of cash, trade receivables, trade and other payables and lease payable on the condensed interim consolidated statements of financial position approximate their fair value due to the relatively short-term maturity of these financial instruments.

Credit risk

Credit risk is the risk of loss associated with a counterparty's inability to fulfill its payment obligations. Cash is held with Canadian and US chartered banks which are closely monitored by management. Management believes that the credit risk concentration with respect to financial instruments is minimal. The maximum exposure to credit risk at period-end is limited to the accounts receivable balance. No ECL has been recorded as at March 31, 2023.

Liquidity risk

Liquidity risk is the risk that the Company will not have sufficient cash resources to meet its financial obligations as they come due. The Company's liquidity and operating results may be adversely affected if the Company's access to the capital market is hindered, whether as a result of a downturn in stock market conditions generally or related to matters specific to the Company. The Company generates cash flow from its financing and revenue activities.

As at March 31, 2023, the Company had a cash balance of \$159,390 (December 31, 2022 – \$183,623) to settle current liabilities of \$2,269,461 (December 31, 2022 – \$2,265,489). The undiscounted contractual maturity of all financial liabilities for the period ended March 31, 2023 is as follows:

	Total	Within 1 year	1 to 3 years	3 to 5 years
	\$	\$	\$	\$
Accounts payable and accrued liabilities	1,043,493	1,043,493	=	-
Convertible note	927,985	927,985	-	-
Convertible grid note	6,808,501	-	-	6,808,501
Lease payable	143,734	143,734		-
Total	8,923,713	2,115,212	-	6,808,501

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company does not hold any instruments subject to interest rate risk as at March 31, 2023.

Notes to the Condensed Interim Consolidated Financial Statements March 31, 2023

(Expressed in Canadian Dollars)

Foreign currency risk

The Company operates in Canada and the US and is exposed to foreign exchange risk with respect to USD. The Company normally raises funds in Canadian dollars for its operations in the US. Foreign exchange risk arises on cash, trade receivables and trade payables from operations in the US. The Company believes that its results of operations and cash flows would be affected by a sudden change in foreign exchange rates.

As at March 31, 2023, and December 31, 2022 the Company had the following financial assets and financial liabilities in USD:

	March 31,	December
	2023	31, 2022
	\$	\$
Cash	114,766	128,564
Trade receivables	158,817	121,789
Note receivable	27,236	26,580
Trade and other payables	(365,700)	(240,583)
Convertible note	(671,428)	(653,313)
Convertible grid note	(3,419,288)	(2,783,216)
Lease obligations	(132,447)	(295,698)
Net exposure to USD	(4,288,044)	(3,695,877)

Had the value of the USD increased or decreased by 1%, the net loss and comprehensive loss would have increased or decreased by USD \$42,880 (December 31, 2022 – USD \$36,959), respectively, as a result of this exposure.

20. Contingencies

Although the possession, cultivation, and distribution of cannabis for recreational and medical use is permitted in the State of California, cannabis is a Schedule-I controlled substance and its use remains a violation of federal law in the US.

The Company's operations are subject to a variety of local and state regulation. Failure to comply with one or more of those regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company ceasing operations in that specific state or local jurisdiction. While management of the Company believes that the Company is in compliance with applicable local and state regulations as at December 31, 2022, cannabis regulations continue to evolve and are subject to differing interpretations. As a result, the Company may be subject to regulatory fines, penalties, or restrictions in the future.

21. Subsequent Events

On April 20, 2023, 100,000 options granted on April 20, 2018, at an exercise price of \$0.87 per share, expired unexercised.